Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents

Mathematical Biosciences

Volumn 245, Issue 1, 2013, Pages 22-30

  Rong, Libin ^a   Perelson, Alan S ^b  

^a OAKLAND UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Age structured model; Antiviral therapy; Hepatitis C virus; Intracellular viral RNA; Multiscale model; Stability; Viral kinetics

Indexed keywords

AGE STRUCTURED MODEL; ANTIVIRAL THERAPY; HEPATITIS C VIRUS; MULTI-SCALE MODELING; VIRAL RNA;

ANTIVIRAL AGENTS; C (PROGRAMMING LANGUAGE); CONVERGENCE OF NUMERICAL METHODS; DYNAMICS; ENZYME ACTIVITY; HOSPITAL DATA PROCESSING; RNA; SURFACE MORPHOLOGY; VIRUSES;

PATIENT TREATMENT;

ANTIVIRUS AGENT; INTERFERON; VIRUS RNA;

HEPATITIS; NUMERICAL MODEL; RNA; VIRAL DISEASE;

ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PREDICTION; RNA REPLICATION; STEADY STATE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION;

HEPATITIS C VIRUS;

AGE-STRUCTURED MODEL; ANTIVIRAL THERAPY; HEPATITIS C VIRUS; INTRACELLULAR VIRAL RNA; MULTISCALE MODEL; STABILITY; VIRAL KINETICS;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MATHEMATICAL CONCEPTS; MODELS, BIOLOGICAL; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 84883247224     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2013.04.012     Document Type: Article

References (46)

1. World Health Organization. Hepatitis C. Fact sheet No. 164. Revised June 2011. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
2. Foster G.R. Past, present, and future hepatitis C treatments. Semin. Liver Dis. 2004, 24(Suppl. 2):97.
3. Fusco D.N., Chung R.T. Novel therapies for hepatitis C: insights from the structure of the virus. Annu. Rev. Med. 2012, 63:373.
4. Hoofnagle J.H. A step forward in therapy for hepatitis C. N. Engl. J. Med. 2009, 360:1899.
5. Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132:1979.
6. Rice C.M. New insights into HCV replication: potential antiviral targets. Top Antivir. Med. 2011, 19:117.
7. Poordad F., Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J. Viral Hepat. 2012, 19:449.
8. Sarrazin C., Hezode C., Zeuzem S., Pawlotsky J.M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 2012, 56(Suppl. 1):S88.
9. Gao M., Nettles R.E., Belema M., Snyder L.B., Nguyen V.N., Fridell R.A., Serrano-Wu M.H., Langley D.R., Sun J.H., O'Boyle D.R., Lemm J.A., Wang C., Knipe J.O., Chien C., Colonno R.J., Grasela D.M., Meanwell N.A., Hamann L.G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465:96.
10. Gane E.J., Rouzier R., Stedman C., Wiercinska-Drapalo A., Horban A., Chang L., Zhang Y., Sampeur P., Najera I., Smith P., Shulman N.S., Tran J.Q. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J. Hepatol. 2011, 55:972.
11. Forestier N., Larrey D., Marcellin P., Guyader D., Patat A., Rouzier R., Smith P.F., Qin X., Lim S., Bradford W., Porter S., Seiwert S.D., Zeuzem S. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C. J. Infect. Dis. 2011, 204:601.
12. Ciesek S., von Hahn T., Manns M.P. Second-wave protease inhibitors: choosing an heir. Clin. Liver Dis. 2011, 15:597.
13. Schaefer E.A., Chung R.T. Anti-hepatitis C virus drugs in development. Gastroenterology 2012, 142:1340. e1.
14. Herrmann E., Neumann A.U., Schmidt J.M., Zeuzem S. Hepatitis C virus kinetics. Antivir. Ther. 2000, 5:85.
15. Guedj J., Rong L., Dahari H., Perelson A.S. A perspective on modelling hepatitis C virus infection. J. Viral Hepat. 2010, 17:825.
16. Rong L., Perelson A.S. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit. Rev. Immunol. 2010, 30:131.
17. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103.
18. Lau J.Y., Tam R.C., Liang T.J., Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002, 35:1002.
19. Pawlotsky J.M., Dahari H., Neumann A.U., Hezode C., Germanidis G., Lonjon I., Castera L., Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004, 126:703.
20. Herrmann E., Lee J., Marinos G., Modi M., Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351.
21. Dixit N.M., Layden-Almer J.E., Layden T.J., Perelson A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922.
22. Layden-Almer J.E., Ribeiro R.M., Wiley T., Perelson A.S., Layden T.J. Viral dynamics and response differences in HCV-infected african american and white patients treated with IFN and ribavirin. Hepatology 2003, 37:1343.
23. Guedj J., Neumann A.U. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J. Theor. Biol. 2010, 267:330.
24. Guedj J., Dahari H., Rong L., Sansone N.D., Nettles R.E., Cotler S.J., Layden T.J., Uprichard S.L., Perelson A.S. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. USA 2013, 110:3991.
25. Rong L., Guedj J., Dahari H., Coffield D.J., Levi M., Smith P., Perelson A.S. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput. Biol. 2013, 9:e1002959.
26. Nelson P.W., Gilchrist M.A., Coombs D., Hyman J.M., Perelson A.S. An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells. Math. Biosci. Eng. 2004, 1:267.
27. Rong L., Feng Z., Perelson A.S. Mathematical modeling of HIV-1 infection and drug therapy. Mathematical Modeling of Biosystems 2008, 87. Springer-Verlag.
28. Gripenberg G., Londen S.O., Staffans O. Volterra Integral and Functional Equations 1990, Cambridge University Press, New York.
29. Thieme H.R. Semiflows generated by Lipschitz perturbations of non-densely defined operators. Differ. Integral Equ. 1990, 3:1035.
30. Webb G.F. Theory of Nonlinear Age-dependent Population Dynamics 1985, CRC Press.
31. Thieme H.R., Castillo-Chavez C. How may infection-age-dependent infectivity affect the dynamics of HIV/AIDS?. SIAM J. Appl. Math. 1993, 53:1447.
32. Feng Z., Iannelli M., Milner F. A two-strain TB model with age-structure. SIAM J. Appl. Math. 2002, 62:1634.
33. Rong L., Feng Z., Perelson A.S. Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy. SIAM J. Appl. Math. 2007, 67:731.
34. Lin K., Kwong A.D., Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother. 2004, 48:4784.
35. Hsu C.S., Hsu S.J., Chen H.C., Tseng T.C., Liu C.H., Niu W.F., Jeng J., Liu C.J., Lai M.Y., Chen P.J., Kao J.H., Chen D.S. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl. Acad. Sci. USA 2011, 108:3719.
36. Guedj J., Dahari H., Perelson A.S. Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy. Proc. Natl. Acad. Sci. USA 2011, 108:E302.
37. Rong L., Dahari H., Ribeiro R.M., Perelson A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2010, 2:30ra32.
38. Rong L., Ribeiro R.M., Perelson A.S. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull. Math. Biol. 2012, 74:1789.
39. Guedj J., Perelson A.S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011, 53:1801.
40. Guedj J., Dahari H., Pohl R.T., Ferenci P., Perelson A.S. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J. Hepatol. 2012, 56:1019.
41. Guedj J., Dahari H., Shudo E., Smith P., Perelson A.S. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine. Hepatology 2012, 55:1030.
42. Adiwijaya B.S., Herrmann E., Hare B., Kieffer T., Lin C., Kwong A.D., Garg V., Randle J.C., Sarrazin C., Zeuzem S., Caron P.R. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 2010, 6:e1000745.
43. Adiwijaya B.S., Kieffer T.L., Henshaw J., Eisenhauer K., Kimko H., Alam J.J., Kauffman R.S., Garg V. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput. Biol. 2012, 8:e1002339.
44. Dahari H., Guedj J., Perelson A.S., Layden T.J. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr. Hepat. Rep. 2011, 10:214.
45. Chaterjee A., Guedj J., Perelson A.S. Mathematical modeling of HCV infection: what can it teach us in the era of direct antiviral agents?. Antivir. Ther. 2012, 17:1171.
46. Chaterjee A., Smith P.F., Perelson A.S. Hepatitis C viral kinetics: the past, present and future. Clin. Liver Dis. 2013, 17:13.